Alvotech

Contributing Author

Recent Articles by Alvotech

11 hours	Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab) ALVO GlobeNewswire
11 hours	Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab) ALVO GlobeNewswire
Jun-23	European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea (aflibercept) ALVO GlobeNewswire
Jun-23	European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea (aflibercept) ALVO GlobeNewswire
Jun-11	Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors ALVO GlobeNewswire
Jun-11	Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors ALVO GlobeNewswire
Jun-06	Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami ALVO GlobeNewswire
Jun-06	Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami ALVO GlobeNewswire
Jun-05	Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) ALVO GlobeNewswire
Jun-05	Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) ALVO GlobeNewswire
Jun-04	Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million ALVO GlobeNewswire
Jun-04	Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million ALVO GlobeNewswire
Jun-04	Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares ALVO GlobeNewswire
Jun-04	Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia ALVO GlobeNewswire
Jun-02	Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY ALVO GlobeNewswire
Jun-02	Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY ALVO GlobeNewswire
May-28	Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe ALVO GlobeNewswire
May-28	Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe ALVO GlobeNewswire
May-26	Alvotech Annual General Meeting to be held June 25, 2025 ALVO GlobeNewswire
May-23	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-19	Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm ALVO GlobeNewswire
May-19	Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today ALVO GlobeNewswire
May-16	Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm ALVO GlobeNewswire
May-16	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-13	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-09	Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada ALVO GlobeNewswire
May-09	Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada ALVO GlobeNewswire
May-09	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
May-08	Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm ALVO GlobeNewswire
May-07	Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update ALVO GlobeNewswire
May-07	Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update ALVO GlobeNewswire
May-07	Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 ALVO GlobeNewswire
May-07	Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 ALVO GlobeNewswire
May-05	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) ALVO GlobeNewswire
May-05	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) ALVO GlobeNewswire
May-02	Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) ALVO GlobeNewswire
May-02	Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT ALVO GlobeNewswire

Alvotech

Recent Articles by Alvotech

Upgrade your FINVIZ experience